Roche denies rumors it will shop diabetes unit, earnings

Roche (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications.

The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and Avastin, bring in annual revenue of more than 20 billion Swiss francs, Reuters reported, and they face incoming competition from biosimilar copies. The 1st copies of Rituxan and Herceptin could hit the European market later this year, the news outlet said.

Get the full story at our sister site, Drug Delivery Business News.

The post Roche denies rumors it will shop diabetes unit, earnings appeared first on MassDevice.

from MassDevice http://ift.tt/2jXXeN9